

A structural variation reference for medical and population genetics

<https://doi.org/10.1038/s41586-020-2287-8>

Received: 2 March 2019

Accepted: 31 March 2020

Published online: 27 May 2020

Open access

 Check for updates

Ryan L. Collins^{1,2,3,157}, Harrison Brand^{1,2,4,157}, Konrad J. Karczewski^{1,5}, Xuefang Zhao^{1,2,4}, Jessica Alfoldi^{1,5}, Laurent C. Franciolini^{1,5,6}, Amit V. Khera^{1,2}, Chelsea Lowther^{1,2,4}, Laura D. Gauthier^{1,7}, Harold Wang^{1,2}, Nicholas A. Watts^{1,6}, Matthew Solomonson^{1,5}, Anne O'Donnell-Luria^{1,5}, Alexander Baumann⁷, Ruchi Munshi⁷, Mark Walker^{1,7}, Christopher W. Whelan⁷, Yongqing Huang⁷, Ted Brookings⁷, Ted Sharpe⁷, Matthew R. Stone^{1,2}, Elise Valkanas^{1,2,3}, Jack Fu^{1,2,4}, Grace Tiao^{1,5}, Kristen M. Laricchia^{1,5}, Valentin Ruano-Rubio⁷, Christine Stevens¹, Namrata Gupta¹, Caroline Cusick¹, Lauren Margolin¹, Genome Aggregation Database Production Team*, Genome Aggregation Database Consortium*, Kent D. Taylor⁸, Henry J. Lin⁸, Stephen S. Rich⁹, Wendy S. Post¹⁰, Yii-Der Ida Chen⁸, Jerome I. Rotter⁸, Chad Nusbaum^{1,154}, Anthony Philippakis⁷, Eric Lander^{1,11,12}, Stacey Gabriel¹, Benjamin M. Neale^{1,2,5,13}, Sekar Kathiresan^{1,2,6,14}, Mark J. Daly^{1,2,5,13}, Eric Banks⁷, Daniel G. MacArthur^{1,2,5,6,155,156} & Michael E. Talkowski^{1,2,4,13} 

Structural variants (SVs) rearrange large segments of DNA¹ and can have profound consequences in evolution and human disease^{2,3}. As national biobanks, disease-association studies, and clinical genetic testing have grown increasingly reliant on genome sequencing, population references such as the Genome Aggregation Database (gnomAD)⁴ have become integral in the interpretation of single-nucleotide variants (SNVs)⁵. However, there are no reference maps of SVs from high-coverage genome sequencing comparable to those for SNVs. Here we present a reference of sequence-resolved SVs constructed from 14,891 genomes across diverse global populations (54% non-European) in gnomAD. We discovered a rich and complex landscape of 433,371 SVs, from which we estimate that SVs are responsible for 25–29% of all rare protein-truncating events per genome. We found strong correlations between natural selection against damaging SNVs and rare SVs that disrupt or duplicate protein-coding sequence, which suggests that genes that are highly intolerant to loss-of-function are also sensitive to increased dosage⁶. We also uncovered modest selection against noncoding SVs in *cis*-regulatory elements, although selection against protein-truncating SVs was stronger than all noncoding effects. Finally, we identified very large (over one megabase), rare SVs in 3.9% of samples, and estimate that 0.13% of individuals may carry an SV that meets the existing criteria for clinically important incidental findings⁷. This SV resource is freely distributed via the gnomAD browser⁸ and will have broad utility in population genetics, disease-association studies, and diagnostic screening.

SVs are DNA rearrangements that involve at least 50 nucleotides¹. By virtue of their size and abundance, SVs represent an important mutational force that shape genome evolution and function^{2,3}, and contribute to germline and somatic diseases^{9–11}. The profound effect of SVs is also attributable to the numerous mechanisms by which they can disrupt protein-coding genes and *cis*-regulatory architecture¹². SVs can be grouped into mutational classes that include ‘unbalanced’ gains or losses of DNA (for example, copy-number variants, CNVs), and ‘balanced’ rearrangements that occur without corresponding dosage alterations (such as inversions and translocations)¹ (Fig. 1a). Other common forms of SVs include mobile elements that insert themselves throughout the genome, and multiallelic CNVs (MCNVs) that can

exist at high copy numbers¹. More recently, exotic species of complex SVs have been discovered that involve two or more distinct SV signatures in a single mutational event interleaved on the same allele, and can range from CNV-flanked inversions to rare instances of localized chromosome shattering, such as chromothripsis^{13,14}. The diversity of SVs in humans is therefore far greater than has been widely appreciated, as is their influence on genome structure and function.

Although SVs alter more nucleotides per genome than SNVs and short insertion/deletion variants (indels; <50 bp)¹, surprisingly little is known about their mutational spectra on a global scale. The largest published population study of SVs using whole-genome sequencing (WGS) remains the 1000 Genomes Project ($n = 2,504$; 7× sequence

List of affiliations and consortium members appear at the end of the paper.




Fig. 1 | Properties of SVs across human populations. **a**, SV classes catalogued in this study. We also documented unresolved non-reference ‘breakends’ (BNDs), but they were excluded from all analyses as low-quality variants. **b**, After quality control, we analysed 14,237 samples across continental populations, including African/African American (AFR), Latino (AMR), East Asian (EAS), and European (EUR), or other populations (OTH). Three publicly available WGS-based SV datasets are provided for comparison (1000 Genomes Project (1000G), approximately 7× coverage; Genome of the Netherlands Project (GoNL), around 13× coverage; Genotype-Tissue Expression Project (GTEx), approximately 50× coverage)^{1,16,17}. **c**, We discovered 433,371 SVs, and provide counts from previous studies for comparison^{1,16,17}. **d**, A principal component (PC) analysis of genotypes for 15,395 common SVs separated samples along axes corresponding to genetic ancestry. **e**, The median genome contained 7,439 SVs. **f**, Most SVs were small. Expected *Alu*, SVA and LINE1 mobile element insertion peaks are marked at approximately 300 bp, 2.1 kb and 6 kb, respectively. **g**, Most SVs were rare (allele frequency (AF) < 1%), and 49.8% of SVs were singletons (solid bars). **h**, Allele frequencies were inversely correlated with SV size across all 335,470 resolved SVs in unrelated individuals. Values are mean and 95% confidence interval from 100-fold bootstrapping. Colour codes are consistent between **a**, **c**, **e–h**, and between **b** and **d**.

coverage)¹, and the substantial technical challenges of SV discovery from WGS¹⁵ has led to non-uniform SV analyses across contemporary studies^{16–20}. Moreover, short-read WGS is unable to capture a subset of SVs accessible to more expensive niche technologies, such as long-read WGS²¹. Owing to the combination of these challenges, SV references are dwarfed by contemporary resources for short variants, such as the Exome Aggregation Consortium (ExAC) and its successor, the Genome Aggregation Database (gnomAD), which have jointly analysed more than 140,000 individuals^{4,6}. Publicly available resources such as ExAC and gnomAD have transformed many aspects of human genetics, including defining sets of genes constrained against damaging coding mutations⁶ and providing frequency filters for variant interpretation⁵. As short-read WGS is rapidly becoming the predominant technology in large-scale human disease studies, and will probably displace conventional methods for diagnostic screening, there is a mounting need for comparable references of SVs across global populations.

In this study, we developed gnomAD-SV, a sequence-resolved reference for SVs from 14,891 genomes. Our analyses revealed diverse mutational patterns among SVs, and principles of selection acting against reciprocal dosage changes in genes and noncoding *cis*-regulatory

elements. From these analyses, we determined that SVs represent more than 25% of all rare protein-truncating events per genome, emphasizing the unrealized potential of routine SV detection in WGS studies. This SV reference has been integrated into the gnomAD browser (<http://gnomad.broadinstitute.org>) with no restrictions on reuse so that it can be mined for new insights into genome biology and applied as a resource to interpret SVs in diagnostic screening.

SV discovery and genotyping

We analysed WGS data for 14,891 samples (average coverage of 32×) aggregated from large-scale sequencing projects, of which 14,237 (95.6%) passed all quality thresholds, representing a general adult population depleted for severe Mendelian diseases (median age of 49 years) (Supplementary Table 1, Supplementary Figs. 1, 2). This cohort included 46.1% European, 34.9% African or African American, 9.2% East Asian, and 8.7% Latino samples, as well as 1.2% samples from admixed or other populations (Fig. 1). Following family-based analyses using 970 parent–child trios for quality assessments, we pruned all first-degree relatives from the cohort, retaining 12,653 unrelated genomes for subsequent analyses.

We discovered and genotyped SVs using a cloud-based, multi-algorithm pipeline for short-read WGS (Supplementary Fig. 3), which we prototyped in a study of 519 autism quartet families²⁰. This pipeline integrated four orthogonal evidence types to capture SVs across the size and allele frequency spectra, including six classes of canonical SVs (Fig. 1a) and 11 subclasses of complex SVs²² (Fig. 2). We augmented this pipeline with new methods to account for the technical heterogeneity of aggregated datasets (Extended Data Fig. 1, Supplementary Figs. 4, 5), and discovered 433,371 SVs (Fig. 1c). After excluding low-quality SVs, which were predominantly (61.6%) composed of incompletely resolved breakpoint junctions (that is, ‘breakends’) that lack interpretable alternative allele structures for functional annotation and produce high false-discovery rates²⁰ (Extended Data Fig. 2a), we retained 335,470 high-quality SVs for subsequent analyses (Supplementary Table 3). This final set of high-quality SVs corresponded to a median of 7,439 SVs per genome, or more than twice the number of variants per genome captured by previous WGS-based SV studies such as the 1000 Genomes Project (3,441 SVs per genome from approximately 7× coverage WGS), which underscores the benefits of high-coverage WGS and improved multi-algorithm ensemble methods for SV discovery.

Given that there are no gold-standard benchmarking procedures for SVs from WGS, we evaluated the technical qualities of gnomAD-SV using seven orthogonal approaches. These analyses are described in detail in Extended Data Figs. 2, 3, Supplementary Figs. 6–12, Supplementary Table 4 and Supplementary Note 1, but we highlight just a few here to demonstrate that gnomAD-SV conforms to many fundamental principles of population genetics, including Mendelian segregation, genotype distributions, and linkage disequilibrium. We found that the precision of gnomAD-SV was comparable to our previous study of 519 autism quartets that attained a 97% molecular validation rate for all de novo SV predictions²⁰: in gnomAD, analyses of 970 parent–child trios indicated a median Mendelian violation rate of 3.8% and a heterozygous de novo rate of 3.0%. We also observed that 86% of SVs were in Hardy–Weinberg equilibrium, and common SVs were in strong linkage disequilibrium with nearby SNVs or indels (median peak $R^2 = 0.85$). We performed extensive in silico confirmation of 19,316 SVs predicted from short-read WGS using matched long-read WGS from four samples^{21,23}, finding a 94.0% confirmation rate with breakpoint-level read evidence, and revealing that 59.8% of breakpoint coordinates were accurate within a single nucleotide of the long-read data. These and other benchmarking approaches suggested that gnomAD-SV was sufficiently sensitive and specific to be used as a reference dataset for most applications in human genetics.




Fig. 2 | Complex SVs are abundant in the human genome. We resolved 5,295 complex SVs across 11 mutational subclasses, 73.7% of which involved at least one inversion. Each subclass is detailed here, including their mutational signatures, structures, abundance, density of SV sizes (vertical line indicates

median size), and allele frequencies. Five pairs of subclasses have been collapsed into single rows due to mirrored or similar alternative allele structures (for example, dellNV versus INVdel). Two complex SVs did not conform to any subclass (Extended Data Fig. 8).

Population genetics and genome biology

The distribution of SVs across samples matched expectations based on human demographic history, with the top three components of genetic variance separating continental populations (Fig. 1d, Supplementary Fig. 13). African and African American samples exhibited the greatest genetic diversity and their common SVs were in weaker linkage disequilibrium with nearby short variants than Europeans, whereas East Asians featured the highest levels of homozygosity (Fig. 1e, Extended Data Fig. 4a–d, Supplementary Fig. 7). The mutational diversity of gnomAD-SV was extensive: we completely resolved 5,295 complex SVs across 11 mutational subclasses, of which 3,901 (73.7%) involved inverted segments (Fig. 2), confirming that inversion variation is predominantly composed of complex SVs rather than canonical inversions^{1,24}. Across all SV classes, most SVs were small (median size of 331 bp) and rare (allele frequency < 1%; 92% of SVs), with half of all SVs (49.8%) appearing as ‘singletons’ (that is, only one allele observed across all samples) (Fig. 1f,g). Although the proportion of singletons varied by SV class, it was strongly dependent on SV size across all classes, which suggests that the amount of DNA rearranged is a key determinant of selection against most SVs (Fig. 1h, Extended Data Fig. 5a).

Mutation rate estimates for SVs have remained elusive owing to limited sample sizes, poor resolution of conventional technologies, technical challenges of SV discovery, and use of cell line-derived DNA in population studies^{1,25}. Here, we used the Watterson estimator²⁶ to project a mean mutation rate of 0.29 de novo SVs (95% confidence interval 0.13–0.44) per generation in regions of the genome accessible to short-read WGS, or roughly one new SV every 2–8 live births, with mutation rates varying markedly by SV class (Fig. 3a). Although this imperfect method extrapolates from data pooled across unrelated individuals, we previously demonstrated comparable rates from molecularly validated observations in 519 quartet families²⁰. Like mutation rates, the distribution of SVs throughout the genome was non-uniform, significantly correlated with repetitive sequence contexts, and was enriched near centromeres and telomeres²³ (Supplementary Fig. 16). These trends were dependent on SV class, as biallelic deletions and duplications were predominantly enriched at telomeres, whereas MCNVs were enriched in centromeric segmental duplications (Fig. 3b–d). Given the reduced sensitivity of short-read WGS in repetitive sequences, this study certainly underestimates the true SV mutation rates; nevertheless, these

analyses implicate several aspects of chromosomal context and SV class in determining SV mutation rates throughout the genome.

Dosage sensitivity of coding and noncoding loci

Owing to their size and mutational diversity, SVs can have varied consequences on protein-coding genes¹² (Fig. 4a, Supplementary Fig. 17). In principle, any SV can result in predicted loss-of-function (pLoF), either by deleting coding nucleotides or altering open-reading frames. Coding duplications can result in copy-gain of entire genes, or of a subset of exons within a gene (referred to here as intragenic exonic




Fig. 3 | Genome-wide mutational patterns of SVs. **a**, Mutation rates (μ) from the Watterson estimator for each SV class²⁶. Bars represent 95% confidence intervals. Rates of molecularly validated de novo SVs from 519 quartet families are provided for comparison²⁰. **b**, Smoothed enrichment of SVs per 100-kb window across the average of all autosomes normalized by chromosome arm length (a ‘meta-chromosome’) (Supplementary Fig. 16). **c**, The distribution of SVs along the meta-chromosome was dependent on variant class. **d**, SV enrichment by class and chromosomal position provided as mean and 95% confidence intervals (CI). C, centromeric; I, interstitial; T, telomeric. P values were computed using a two-sided t -test and were Bonferroni-adjusted for 21 comparisons. $*P \leq 2.38 \times 10^{-3}$.

duplication, or IED). The average genome in gnomAD-SV contained a mean of 179.8 genes altered by biallelic SVs (144.3 pLoF, 24.3 copy-gain, and 11.2 IED), of which 11.6 were predicted to be completely inactivated by homozygous pLoF (Fig. 4b, Extended Data Fig. 4e–h). When restricted to rare (allele frequency < 1%) SVs, we observed a mean of 10.2 altered genes per genome (5.5 pLoF, 3.4 copy-gain, and 1.3 IED). By comparison, a companion gnomAD paper estimated 122.4 pLoF short variants per genome, of which 16.3 were rare⁴. These analyses suggest that 29.4% of rare heterozygous gene inactivation events per individual are contributed by SVs, or conservatively 25.2% of pLoF events if we exclude IEDs given the context-dependence of their functional impact.

A fundamental question in human genetics is the degree to which natural selection acts on coding and noncoding loci. The proportion of singleton variants has been established as a proxy for strength of selection⁶; however, this metric is confounded for SVs given the strong correlation between allele frequency and SV size, among other factors. Therefore, we developed a new metric, adjusted proportion of singletons (APS), to account for SV class, size, genomic context, and other technical covariates (Extended Data Fig. 5, Supplementary Fig. 14). Under this normalized APS metric, a value of zero corresponds to a singleton proportion comparable to intergenic SVs, whereas values greater than zero reflect purifying selection, similar to the ‘mutability-adjusted proportion of singletons’ (MAPS) metric used for SNVs⁶. Applying this APS model revealed signals of pervasive selection against nearly all classes of SVs that overlap genes, including intronic SVs, whole-gene inversions, SVs in gene promoters, and deletions as small as a single exon (Fig. 4c, Extended Data Fig. 6, Supplementary Fig. 18). The one notable exception was copy-gain duplications, which showed no clear evidence of selection beyond what could already be explained by their sizes, which were vastly larger than non-copy-gain duplications (median copy-gain duplication size = 134.8 kb; median non-copy-gain duplication size = 2.7 kb; one-tailed Wilcoxon test, $W=1.18 \times 10^8, P<10^{-100}$). This result could have numerous explanations, but it is consistent with the known diverse evolutionary roles of gene duplication events, including positive selection reported in humans^{27,28}.

Methods that quantify evolutionary constraint on a per-gene basis, such as the probability of intolerance to heterozygous pLoF variation (pLI)⁶ and the pLoF observed/expected upper fraction (LOEUF)⁴, have become core resources in human genetics. Nearly all existing metrics, including pLI and LOEUF, are derived from SNVs. Although previous studies have attempted to compute similar scores using large CNVs detected by microarray and exome sequencing^{29,30}, or to correlate deletions with pLI¹⁸, no gene-level metrics comparable to LOEUF exist for SVs at WGS resolution. To gain insight into this problem, we built a model to estimate the depletion of rare SVs per gene compared to expectations based on gene length, genomic context, and the structure of exons and introns. This model is imperfect, as current sample sizes are too sparse to derive precise gene-level metrics of constraint from SVs. Nevertheless, we found strong concordance between the depletion of rare pLoF SVs and existing pLoF and missense SNV constraint metrics⁴ (pLoF Spearman correlation test, $\rho=0.90, P<10^{-100}$) (Fig. 4d, Supplementary Fig. 19). Notably, a comparable positive correlation was also observed for copy-gain SVs and SNV constraint (pLoF Spearman correlation test, $\rho=0.78, P<10^{-100}$), whereas a weaker yet significant correlation was detected for IEDs (pLoF Spearman correlation test, $\rho=0.58, P=2.0 \times 10^{-11}$). As orthogonal support for these trends, we identified an inverse correlation between APS and SNV constraint across all functional categories of SVs, which was consistent with our observed depletion of rare, functional SVs in constrained genes (Extended Data Fig. 6f). These comparisons confirm that selection against most classes of gene-altering SVs mirrors patterns observed for short variants^{18,30}. They further suggest that SNV-derived constraint metrics such as LOEUF capture a general correspondence between haploinsufficiency and triplosensitivity for a large fraction of genes in




Fig. 4 | Pervasive selection against SVs in genes mirrors coding short variants. **a**, Four categories of gene-overlapping SVs, with counts of total SVs, median SV size, and mean SVs per gene in gnomAD-SV. **b**, Count of genes altered by SVs per genome. Horizontal lines indicate medians. Sample sizes per category listed in Supplementary Table 9. **c**, APS value for SVs overlapping genes. Bars indicate 100-fold bootstrapped 95% confidence intervals. SVs per category listed in Supplementary Table 9. **d**, Relationships of constraint against pLoF SNVs versus gene-overlapping SVs in 100 bins of around 175 genes each, ranked by SNV constraint⁴. Correlations were assessed with a two-sided Spearman correlation test. Solid lines represent 21-point rolling means. See Supplementary Fig. 19 for comparisons to missense constraint.

the genome. It therefore appears that the most highly pLoF-constrained genes not only are sensitive to pLoF, but also are more likely to be intolerant to increased dosage and other functional alterations.

In contrast to the well-studied effects of coding variation, the effects of noncoding SVs on regulatory elements are largely unknown. There are a handful of examples of SVs with strong noncoding effects, although they are scarce in humans and model organisms^{31,32}. In gnomAD-SV, we explored noncoding dosage sensitivity across 14 regulatory element classes, ranging from high-confidence experimentally validated enhancers to large databases of computationally predicted elements (Supplementary Table 5). We found that noncoding CNVs overlapping most element classes had increased proportions of singletons, although none exceeded the APS observed for pLoF SVs (Fig. 5a). In general, the effects of noncoding deletions appeared stronger than noncoding duplications, and CNVs predicted to delete or duplicate entire elements were under stronger selection than partial element disruption (Fig. 5b). We also observed that primary sequence conservation was correlated with selection against noncoding CNVs (Fig. 5c, d), which provides a foothold for future work on interpretation and functional effect prediction for noncoding SVs. Broadly, these results followed trends we observed for protein-coding SVs, which we interpreted as evidence for weak but widespread selection against CNVs altering most classes of annotated regulatory elements.

Trait association and clinical genetics

Most large-scale trait association studies have only considered SNVs in genome-wide association studies (GWAS). Taking advantage of the sample size and resolution of gnomAD-SV, we evaluated whether SNVs associated with human traits might be in linkage disequilibrium with SVs not directly genotyped in GWAS. We identified 15,634 common SVs (allele frequency >1%) in strong linkage disequilibrium ($R^2 \geq 0.8$) with at least one common short variant (Supplementary




Fig. 5 | Dosage sensitivity in the noncoding genome. **a**, Strength of selection (APS) for noncoding CNVs overlapping 14 categories of noncoding elements (Supplementary Table 5). Bars reflect 95% confidence intervals from 100-fold bootstrapping. Each category was compared to neutral variation (APS = 0) using a one-tailed *t*-test. Categories surpassing Bonferroni-corrected significance for 32 comparisons are indicated with dark shaded points. SVs per category listed in Supplementary Table 9. DEL, deletion; DUP, duplication; TAD, topologically associating domain; TF, transcription factor. **b**, CNVs that completely covered elements ('full') had significantly higher average APS values than CNVs that only partially covered elements ('partial'). *P* values calculated using a two-tailed paired two-sample *t*-test for the 14 categories from **a**. **c, d**, Spearman correlations between sequence conservation and APS for noncoding deletions ($n=143,353$) (**c**) and duplications ($n=30,052$) (**d**). Noncoding CNVs were sorted into 100-percentile bins based on the sum of the phastCons scores overlapped by the CNV. Correlations were assessed with a two-sided Spearman correlation test. Solid lines represent 21-point rolling means.

Fig. 7), 14.8% of which matched a reported association from the NHGRI-EBI GWAS catalogue or a recent analysis of 4,203 phenotypes in the UK Biobank^{33,34}. Common SVs in linkage disequilibrium with GWAS variants were enriched for genic SVs across multiple functional categories (Supplementary Table 6), and included candidate SVs such as a deletion of a thyroid enhancer in the first intron of *ATP6VOD1* at a hypothyroidism-associated locus³⁴ (Extended Data Fig. 7). We also identified matches for previously proposed causal SVs tagged by common SNVs, including pLoF deletions of *CFHR3* or *CFHR1* in nephropathies and of *LCE3B* or *LCE3C* in psoriasis^{35,36}. These results demonstrate the value of imputing SVs into GWAS, and for the eventual unification of short variants and SVs in all trait association studies. Given the potential value of this resource, we have released these linkage disequilibrium maps in Supplementary Table 7.

As genomic medicine advances towards diagnostic screening at sequence resolution, computational methods for variant discovery from WGS and population references for interpretation will become indispensable. One category of disease-associated SVs, recurrent CNVs mediated by homologous segmental duplications known as genomic disorders, are particularly important because they collectively represent a common cause of developmental disorders³⁷. Accurate detection of large, repeat-mediated CNVs is thus crucial for WGS-based diagnostic testing as chromosomal microarray is the recommended first-tier diagnostic screen at present for unexplained developmental disorders³⁷. Using gnomAD-SV, we evaluated our ability to detect genomic disorders in WGS data by calculating CNV carrier frequencies for 49 genomic disorders across 10,047 unrelated samples with no known neuropsychiatric disease and found that CNV carrier frequencies in gnomAD-SV

were consistent with those reported from chromosomal microarray in the UK Biobank³⁸ ($R^2=0.669$; Pearson correlation test, $P=7.38 \times 10^{-13}$) (Fig. 6a, Supplementary Table 8, Supplementary Fig. 20). The frequencies of carriers of genomic disorders did not vary significantly among populations, with the exception of duplications of *NPHP1* at 2q13, in which carrier frequencies in East Asian samples were up to 4.6-fold higher than in other populations, further highlighting the potential for variant interpretation to be confounded by the limited diversity of existing SV references (Supplementary Fig. 21).

In the context of variant interpretation, the current gnomAD-SV resource will permit a screening threshold of allele frequencies less than 0.1% when matching on ancestry to the populations sampled here, and allele frequencies less than 0.004% globally. In the current release, we catalogued at least one pLoF or copy-gain variant for 36.9% and 23.7% of all autosomal genes, respectively, and 490 genes with at least one homozygous pLoF SV (Fig. 6b, Extended Data Fig. 6e, Supplementary Fig. 22). We also benchmarked carrier rates for several categories of clinically relevant variants in gnomAD-SV. First, 0.32% of samples carried a very rare (allele frequency < 0.1%) SV resulting in pLoF of a gene for which incidental findings are clinically actionable, nearly half of which (that is, 0.13% of all samples) would meet diagnostic criteria as pathogenic or likely pathogenic based upon the American College of Medical Genetics (ACMG) recommendations⁷ (Fig. 6c). Second, 7.22% of individuals were heterozygous carriers of rare pLoF SVs in known recessive developmental disorder genes³⁹. Third, we estimated that 3.8% of the general population (95% confidence interval of 3.2–4.6%) carries at least one very large (≥ 1 Mb) rare autosomal SV, roughly half of which (45.2%) were balanced or complex (Fig. 6d). Among these was an example of localized chromosome shattering involving at least 49 breakpoints, yet resulting in largely balanced products, reminiscent of chromothripsis, in an adult with no known severe disease or DNA repair defect^{13,14,22} (Fig. 6e, Extended Data Fig. 8). Collectively, these analyses highlight the potential of gnomAD-SV and WGS-based SV methods to augment disease-association studies and clinical interpretation across a broad spectrum of variant classes and study designs.

Discussion

Human genetic research and clinical diagnostics are becoming increasingly invested in capturing the complete landscape of variation in individual genomes. Ambitious international initiatives to generate short-read WGS in many thousands of individuals from common disease cohorts have underwritten this goal^{40,41}, and millions of genomes will be sequenced in the coming years from national biobanks^{42,43}. A central challenge to these efforts will be the uniform analysis and interpretation of all variation accessible to WGS, particularly SVs, which are frequently invoked as a source of added value offered by WGS. Indeed, early WGS studies in cardiovascular disease and autism have been largely consistent in their analyses of short variants, but every study has differed in its analysis of SVs^{18–20,40,41}. Thus, while ExAC and gnomAD have prompted remarkable advances in medical and population genetics for short variants, the same gains have not yet been realized for SVs. Although gnomAD-SV is not exhaustively comprehensive, it was derived from WGS methods and a reference genome that match those currently used in many research and clinical settings, which will help to facilitate the eventual standardization of SV discovery, analysis, and interpretation across studies.

Most foundational assumptions about human genetic variation were consistent between SVs and short variants in gnomAD, most notably that SVs segregate stably on haplotypes in the population and experience selection commensurate with their predicted biological consequences. This study also spotlights unique aspects of SVs, such as their remarkable mutational diversity, their varied functional effects on coding sequence, and the intense selection against large and complex




Fig. 6 | gnomAD-SV as a resource for clinical WGS interpretation.

a, Comparison of carrier frequencies for 49 putatively disease-associated deletions (red) and duplications (blue) at genomic disorder loci between gnomAD-SV and microarray analyses in the UK Biobank (UKBB)³⁸. Light bars indicate binomial 95% confidence intervals. Solid grey line represents linear best fit. **b**, At least one pLoF or copy-gain SV was detected in 36.9% and 23.7% of all autosomal genes, respectively. ‘Constrained’ and ‘unconstrained’ includes the least and most constrained 15% of all genes based on LOEUF⁴, respectively. **c**, Carrier rates for very rare (allele frequency < 0.1%) pLoF SVs in medically relevant genes across several gene lists^{7,39,44}. SVs per category listed in Supplementary Table 9. **d**, Carrier rates for very large (≥ 1 Mb) rare autosomal SVs among 12,653 genomes. Bars represent binomial 95% confidence intervals. **e**, A complex SV involving at least 49 breakpoints and seven chromosomes (also see Extended Data Fig. 8). Teal arrows indicate insertion point into chromosome 1.

SVs. Our analyses also demonstrate that gene-altering effects of SVs beyond pLoF are remarkably similar to the mutational constraints of SNVs, and that SNV constraint metrics are not specific to haploinsufficiency but underlie a general intolerance to alterations of both gene dosage and structure. Beyond genes, we uncovered widespread but modest selection against noncoding dosage alterations of many families of *cis*-regulatory elements. This study represents one of the largest empirical assessments of noncoding dosage sensitivity in humans, and underscores that: (1) few—if any—classes of noncoding *cis*-regulatory variants are likely to experience selection as strong as protein-truncating variants; (2) sequence conservation is unsurprisingly one of the strongest features associated with selection against noncoding SVs; and (3) current WGS sample sizes are vastly underpowered to identify individual constrained functional elements in the noncoding genome.

The value of the multi-algorithm ensemble approach and deep WGS is evident in the improved sensitivity of SV detection in gnomAD-SV. However, short-read WGS remains limited by comparison to emerging long-read technologies²¹. Given that short-read WGS is blind to a disproportionate fraction of repeat-mediated SVs and small insertions by comparison to long-read methods, this study certainly underestimates the true mutation rates within such hypermutable regions. Similarly, although our approach involves extensive methods to resolve complex SV alleles, some variants such as high-copy-state MCNVs often involve complicated haplotype configurations, and we expect that emerging de novo assembly and graph-based genome representations will greatly expand our knowledge of such SVs^{21,23}. Nonetheless, 92.7% of all known autosomal protein-coding nucleotides are not localized to simple- or low-copy repeats, and therefore we expect that the catalogues of SVs accessible to short-read WGS across large populations like gnomAD-SV will capture a majority of the most interpretable gene-disrupting SVs in humans.

The scale of short-read WGS datasets currently in production has magnified the need for publicly available SV resources, and gnomAD-SV represents an initial effort to fill this void. Although these data remain insufficient to derive accurate estimates of gene-level constraint, sequence-specific mutation rates, and intolerance to noncoding SVs, they provide a step towards these goals and reinforce the value of data sharing and harmonized analyses of aggregated genomic data sets. These data have been made available without restrictions on reuse (<https://gnomad.broadinstitute.org>), and this resource will catalyse new discoveries in basic research while providing immediate clinical utility for the interpretation of rare structural rearrangements across human populations.

Online content

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41586-020-2287-8>.

- Sudmant, P. H. et al. An integrated map of structural variation in 2,504 human genomes. *Nature* **526**, 75–81 (2015).
- Perry, G. H. et al. Copy number variation and evolution in humans and chimpanzees. *Genome Res.* **18**, 1698–1710 (2008).
- Weischenfeldt, J., Symmons, O., Spitz, F. & Korbel, J. O. Phenotypic impact of genomic structural variation: insights from and for human disease. *Nat. Rev. Genet.* **14**, 125–138 (2013).
- Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* <https://doi.org/10.1038/s41586-020-2308-7> (2020).
- Walsh, R. et al. Reassessment of Mendelian gene pathogenicity using 7,855 cardiomyopathy cases and 60,706 reference samples. *Genet. Med.* **19**, 192–203 (2017).
- Lek, M. et al. Analysis of protein-coding genetic variation in 60,706 humans. *Nature* **536**, 285–291 (2016).
- Green, R. C. et al. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. *Genet. Med.* **15**, 565–574 (2013).
- Karczewski, K. J. et al. The ExAC browser: displaying reference data information from over 60 000 exomes. *Nucleic Acids Res.* **45** (D1), D840–D845 (2017).
- Sebat, J. et al. Strong association of *de novo* copy number mutations with autism. *Science* **316**, 445–449 (2007).
- Beroukhim, R. et al. The landscape of somatic copy-number alteration across human cancers. *Nature* **463**, 899–905 (2010).
- Talkowski, M. E. et al. Sequencing chromosomal abnormalities reveals neurodevelopmental loci that confer risk across diagnostic boundaries. *Cell* **149**, 525–537 (2012).
- Hurles, M. E., Dermitzakis, E. T. & Tyler-Smith, C. The functional impact of structural variation in humans. *Trends Genet.* **24**, 238–245 (2008).
- Chiang, C. et al. Complex reorganization and predominant non-homologous repair following chromosomal breakage in karyotypically balanced germline rearrangements and transgenic integration. *Nat. Genet.* **44**, 390–397 (2012).
- Kloosterman, W. P. et al. Chromothripsy as a mechanism driving complex *de novo* structural rearrangements in the germline. *Hum. Mol. Genet.* **20**, 1916–1924 (2011).
- Kosugi, S. et al. Comprehensive evaluation of structural variation detection algorithms for whole genome sequencing. *Genome Biol.* **20**, 117 (2019).
- Hehir-Kwa, J. Y. et al. A high-quality human reference panel reveals the complexity and distribution of genomic structural variants. *Nat. Commun.* **7**, 12989 (2016).
- Chiang, C. et al. The impact of structural variation on human gene expression. *Nat. Genet.* **49**, 692–699 (2017).
- Brandler, W. M. et al. Paternally inherited *cis*-regulatory structural variants are associated with autism. *Science* **360**, 327–331 (2018).
- Turner, T. N. et al. Genomic patterns of *de novo* mutation in simplex autism. *Cell* **171**, 710–722.e12 (2017).
- Werling, D. M. et al. An analytical framework for whole-genome sequence association studies and its implications for autism spectrum disorder. *Nat. Genet.* **50**, 727–736 (2018).
- Chaisson, M. J. P. et al. Multi-platform discovery of haplotype-resolved structural variation in human genomes. *Nat. Commun.* **10**, 1784 (2019).
- Collins, R. L. et al. Defining the diverse spectrum of inversions, complex structural variation, and chromothripsy in the morbid human genome. *Genome Biol.* **18**, 36 (2017).
- Audano, P. A. et al. Characterizing the major structural variant alleles of the human genome. *Cell* **176**, 663–675.e19 (2019).
- Brand, H. et al. Paired-duplication signatures mark cryptic inversions and other complex structural variation. *Am. J. Hum. Genet.* **97**, 170–176 (2015).
- Conrad, D. F. et al. Origins and functional impact of copy number variation in the human genome. *Nature* **464**, 704–712 (2010).
- Watterson, G. A. On the number of segregating sites in genetical models without recombination. *Theor. Popul. Biol.* **7**, 256–276 (1975).
- Dennis, M. Y. & Eichler, E. E. Human adaptation and evolution by segmental duplication. *Curr. Opin. Genet. Dev.* **41**, 44–52 (2016).

28. Kondrashov, F. A., Rogozin, I. B., Wolf, Y. I. & Koonin, E. V. Selection in the evolution of gene duplications. *Genome Biol.* **3**, research0008.1 (2002).
29. Huang, N., Lee, I., Marcotte, E. M. & Hurles, M. E. Characterising and predicting haploinsufficiency in the human genome. *PLoS Genet.* **6**, e1001154 (2010).
30. Ruderfer, D. M. et al. Patterns of genic intolerance of rare copy number variation in 59,898 human exomes. *Nat. Genet.* **48**, 1107–1111 (2016).
31. Franke, M. et al. Formation of new chromatin domains determines pathogenicity of genomic duplications. *Nature* **538**, 265–269 (2016).
32. Redin, C. et al. The genomic landscape of balanced cytogenetic abnormalities associated with human congenital anomalies. *Nat. Genet.* **49**, 34–45 (2016).
33. Buniello, A. et al. The NHGRI-EBI GWAS Catalog of published genome-wide association studies, targeted arrays and summary statistics 2019. *Nucleic Acids Res.* **47** (D1), D1005–D1012 (2019).
34. Neale, B. UK Biobank GWAS round 2; <http://www.nealelab.is/uk-biobank/> (2018).
35. Xie, J. et al. Fine mapping implicates a deletion of *CFHR1* and *CFHR3* in protection from IgA nephropathy in Han Chinese. *J. Am. Soc. Nephrol.* **27**, 3187–3194 (2016).
36. de Cid, R. et al. Deletion of the late cornified envelope *LCE3B* and *LCE3C* genes as a susceptibility factor for psoriasis. *Nat. Genet.* **41**, 211–215 (2009).
37. Miller, D. T. et al. Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies. *Am. J. Hum. Genet.* **86**, 749–764 (2010).
38. Owen, D. et al. Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. *BMJ Genomics* **19**, 867 (2018).
39. Wright, C. F. et al. Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. *Lancet* **385**, 1305–1314 (2015).
40. Choi, S. H. et al. Association between titin loss-of-function variants and early-onset atrial fibrillation. *J. Am. Med. Assoc.* **320**, 2354–2364 (2018).
41. Natarajan, P. et al. Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. *Nat. Commun.* **9**, 3391 (2018).
42. Collins, F. S. & Varmus, H. A new initiative on precision medicine. *N. Engl. J. Med.* **372**, 793–795 (2015).
43. Sudlow, C. et al. UK biobank: an open access resource for identifying the causes of a wide range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).
44. Rehm, H. L. et al. ClinGen—the Clinical Genome Resource. *N. Engl. J. Med.* **372**, 2235–2242 (2015).
45. Huddleston, J. et al. Discovery and genotyping of structural variation from long-read haploid genome sequence data. *Genome Res.* **27**, 677–685 (2017).
46. Pendleton, M. et al. Assembly and diploid architecture of an individual human genome via single-molecule technologies. *Nat. Methods* **12**, 780–786 (2015).
47. Zhao, X., Weber, A. M. & Mills, R. E. A recurrence-based approach for validating structural variation using long-read sequencing technology. *Gigascience* **6**, 1–9 (2017).
48. ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. *Nature* **489**, 57–74 (2012).
49. Battle, A., Brown, C. D., Engelhardt, B. E. & Montgomery, S. B. Genetic effects on gene expression across human tissues. *Nature* **550**, 204–213 (2017).

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2020

¹Program in Medical and Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ²Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ³Division of Medical Sciences, Harvard Medical School, Boston, MA, USA. ⁴Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA. ⁵Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA. ⁶Department of Medicine, Harvard Medical School, Boston, MA, USA. ⁷Data Science Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁸The Institute for Translational Genomics and Population Sciences, Department of Pediatrics, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA. ⁹Center for Public Health Genomics, University of Virginia, Charlottesville, VA, USA. ¹⁰Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹¹Department of Systems Biology, Harvard Medical School, Boston, MA, USA. ¹²Department of Biology, MIT, Cambridge, MA, USA. ¹³Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹⁴Division of Cardiology, Massachusetts General Hospital, Boston, MA, USA. ¹⁵Present address: Cellarity Inc., Cambridge, MA, USA. ¹⁵Present address: Centre for Population Genomics, Garvan Institute of Medical Research, and UNSW Sydney, Sydney, Australia. ¹⁵Present address: Centre for Population Genomics, Murdoch Children's Research Institute, Melbourne, Australia. ¹⁵These authors contributed equally: Ryan L. Collins, Harrison Brand. ¹⁶e-mail: talkowsk@broadinstitute.org

Genome Aggregation Database Production Team

Jessica Alfoldi^{1,15}, Irina M. Armean^{1,15,16}, Eric Banks⁷, Louis Bergelson⁷, Kristian Cibulskis⁷, Ryan L. Collins^{1,2,3}, Kristen M. Connolly⁷, Miguel Covarrubias⁷, Beryl Cummings^{1,15}, Mark J. Daly^{1,13,15}, Stacey Donnelly¹, Yossi Farjoun⁷, Steven Ferriera¹⁸, Laurent Franciol^{1,15}, Stacey Gabriel¹⁸, Laura D. Gauthier⁷, Jeff Gentry⁷, Namrata Gupta^{1,18}, Thibault Jeandet⁷, Diane Kaplan⁷, Konrad J. Karczewski^{1,15}, Kristen M. Laricchia^{1,15}, Christopher Llanwarne⁷, Eric V. Minikel¹, Ruchi Munshi⁷, Benjamin M. Neale^{1,15}, Sam Novod⁷, Anne H. O'Donnell-Luria^{1,19,20}, Nikelle Petrillo⁷, Timothy Poterba^{1,13,15}, David Rozenzweig⁷, Valentin Ruano-Rubio⁷, Andrea Saltzman¹, Kaitlin E. Samocha²¹, Molly Schleicher¹, Cotton Seed^{13,15}, Matthew Solomonson^{1,15}, Jose Soto⁷, Grace Tiao^{1,15}, Kathleen Tibbets⁷, Charlotte Tolonen⁷, Christopher Vital^{1,15}, Gordon Wade⁷, Arcturus Wang^{1,13,15}, Qingbo Wang^{1,13,15}, James S. Ware^{1,22,23}, Nicholas A. Watts^{1,15}, Ben Weisburd⁴ & Nicola Whiffin^{1,22,23}

¹⁵Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA.

¹⁶European Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. ¹⁷Genomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹⁸Broad Genomics, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹⁹Division of Genetics and Genomics, Boston Children's Hospital, Boston, MA, USA. ²⁰Department of Pediatrics, Harvard Medical School, Boston, MA, USA.

²¹Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, Cambridge, UK. ²²National Heart & Lung Institute and MRC London Institute of Medical Sciences, Imperial College London, London, UK. ²³Cardiovascular Research Centre, Royal Brompton & Harefield Hospitals NHS Trust, London, UK.

Genome Aggregation Database Consortium

Carlos A. Aguilar Salinas²⁴, Tariq Ahmad²⁵, Christine M. Albert^{26,27}, Diego Ardissino²⁸, Gil Atzman^{29,30,31}, John Barnard³², Laurent Beaugerie³³, Emelia J. Benjamin^{34,35,36}, Michael Boehnke³⁷, Lori L. Bonnycastle³⁸, Erwin P. Bottinger³⁹, Donald W. Bowden^{40,41,42}, Matthew J. Bown^{43,44}, John C. Chambers^{45,46,47}, Juliania C. Chan⁴⁸, Daniel Chasman^{6,26}, Judy Cho³⁹, Mina K. Chung³², Bruce Cohen^{6,49}, Adolfo Correa⁵⁰, Dana Dabelea⁵¹, Mark J. Daly^{1,13,15}, Dawood Darbar^{52,53}, Ravindranath Duggirala⁵⁴, Josée Dupuis^{34,55}, Patrick T. Ellinor^{1,56}, Roberto Elosua^{57,58,59}, Jeanette Erdmann^{60,61,62}, Tönu Esko^{1,63}, Martti Färkkilä⁶⁴, Jose Florez^{7,65,66,67}, Andre Franke⁶⁸, Gad Getz^{6,68,70,71,72}, Benjamin Glaser⁷³, Stephen J. Glatt⁷⁴, David Goldstein^{75,76}, Cíclerio Gonzalez⁷⁷, Leif Groop^{78,79}, Christopher Haiman⁸⁰, Craig Hanis⁸¹, Matthew Harms^{82,83}, Mikko Hiltunen⁸⁴, Matti M. Holli⁸⁵, Christina M. Hultman^{86,87}, Mikko Kallela⁸⁸, Jaakko Kaprio^{79,89}, Sekar Kathiresan^{12,6,90}, Bong-Jo Kim⁹¹, Young Jin Kim⁹¹, George Kirov⁹², Jaspal Kooner^{22,46,47}, Seppo Koskinen⁹³, Harlan M. Krumholz⁹⁴, Subra Kugathasan⁹⁵, Soo Heon Kwak⁹⁶, Markku Laakso^{97,98}, Terho Lehtimäki⁹⁹, Ruth J. F. Loos^{39,100}, Steven A. Lubitz^{1,56}, Ronald C. W. Ma^{48,101,102}, Daniel G. MacArthur^{1,15}, Jaume Marrugat^{58,103}, Kari M. Mattila⁹⁹, Steven McCarroll^{13,104}, Mark I. McCarthy^{105,106,107}, Dermot McGovern¹⁰⁸, Ruth McPherson¹⁰⁹, James B. Meigs^{1,6,110}, Olle Melander¹¹¹, Andres Metspalu⁶³, Benjamin M. Neale^{1,15}, Peter M. Nilsson¹¹², Michael C. O'Donovan⁹², Dost Ongur^{6,49}, Lorena Orozco¹¹³, Michael J. Owen⁹², Colin N. A. Palmer¹¹⁴, Aarno Palotie^{13,15,79}, Kyong Soo Park^{96,115}, Carlos Pato¹¹⁶, Ann E. Pulver¹¹⁷, Nazneen Rahman¹¹⁸, Anne M. Remes¹¹⁹, John D. Rioux^{120,121}, Samuli Ripatti^{179,89}, Dan M. Roden^{122,123}, Danish Saleheen^{124,125,123}, Veikko Salomaa¹²⁷, Nilesh J. Samani^{43,44}, Jeremiah Scharf^{2,1,2,13}, Heribert Schunkert^{128,129}, Moore B. Shoemaker¹³⁰, Pamela Sklar^{131,132,133,158}, Hilkka Soininen¹³⁴, Harry Sokol¹³³, Tim Spector¹³⁵, Patrick F. Sullivan^{86,136}, Jaana Suvisaara¹²⁷, E. Shyong Tai^{137,138,139}, Yik Ying Teo^{137,140,141}, Tuomi Tiinamaija^{79,142,143}, Ming Tsuang^{144,145}, Dan Turner¹⁴⁶, Teresa Tusie-Luna^{147,148}, Erkki Virtainainen⁸⁹, James S. Ware^{1,22,23}, Hugh Watkins¹⁴⁹, Rinse K. Weersma¹⁵⁰, Maija Wessman^{79,142}, James G. Wilson¹⁵¹ & Ramnik J. Xavier^{152,153}

²⁴Unidad de Investigación de Enfermedades Metabólicas, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico. ²⁵Peninsula College of Medicine and Dentistry, Exeter, UK. ²⁶Division of Preventive Medicine, Brigham and Women's Hospital, Boston, MA, USA. ²⁷Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. ²⁸Department of Cardiology, University Hospital, Parma, Italy. ²⁹Department of Biology, Faculty of Natural Sciences, University of Haifa, Haifa, Israel. ³⁰Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA. ³¹Department of Genetics, Albert Einstein College of Medicine, Bronx, NY, USA. ³²Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA. ³³Gastroenterology Department, Sorbonne Université, APHP, Saint Antoine Hospital, Paris, France. ³⁴Framingham Heart Study, National Heart, Lung, & Blood Institute and Boston University, Framingham, MA, USA. ³⁵Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA. ³⁶Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, USA. ³⁷Department of Biostatistics, Center for Statistical Genetics, University of Michigan, Ann Arbor, MI, USA. ³⁸National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA. ³⁹The Charles Bronfman Institute for Personalized Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁴⁰Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁴¹Center for Genomics and Personalized Medicine Research, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁴²Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC, USA. ⁴³Department of Cardiovascular Sciences, University of Leicester, Leicester, UK. ⁴⁴Department of Cardiovascular Sciences and NIHR Leicester Biomedical Research Centre, University of Leicester, Leicester, UK.

- ⁴⁵Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
⁴⁶Department of Cardiology, Ealing Hospital NHS Trust, Southall, UK. ⁴⁷Imperial College Healthcare NHS Trust, Imperial College London, London, UK. ⁴⁸Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China. ⁴⁹Program for Neuropsychiatric Research, McLean Hospital, Belmont, MA, USA. ⁵⁰Department of Medicine, University of Mississippi Medical Center, Jackson, MI, USA. ⁵¹Department of Epidemiology, Colorado School of Public Health, Aurora, CO, USA. ⁵²Department of Pharmacology, University of Illinois at Chicago, Chicago, IL, USA. ⁵³Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA. ⁵⁴Department of Genetics, Texas Biomedical Research Institute, San Antonio, TX, USA. ⁵⁵Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA. ⁵⁶Cardiac Arrhythmia Service, Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, USA. ⁵⁷Cardiovascular Epidemiology and Genetics, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Catalonia, Spain. ⁵⁸Centro de Investigación en Red en Enfermedades Cardiovasculares (CIBERCV), Barcelona, Catalonia, Spain. ⁵⁹Department of Medicine, Medical School, University of Vic-Central University of Catalonia, Vic, Catalonia, Spain. ⁶⁰Institute for Cardiogenetics, University of Lübeck, Lübeck, Germany. ⁶¹DZHK (German Research Centre for Cardiovascular Research), partner site Hamburg/Lübeck/Kiel, Lübeck, Germany. ⁶²University Heart Center, Lübeck, Lübeck, Germany. ⁶³Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia. ⁶⁴Clinic of Gastroenterology, Helsinki University Hospital, Helsinki University, Helsinki, Finland. ⁶⁵Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA. ⁶⁶Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA. ⁶⁷Program in Metabolism, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁶⁸Institute of Clinical Molecular Biology (IKMB), Christian-Albrechts-University of Kiel, Kiel, Germany. ⁶⁹Bioinformatics Consortium, Massachusetts General Hospital, Boston, MA, USA. ⁷⁰Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. ⁷¹Cancer Center, Massachusetts General Hospital, Boston, MA, USA. ⁷²Cancer Genome Computational Analysis Group, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁷³Endocrinology and Metabolism Department, Hadassah-Hebrew University Medical Center, Jerusalem, Israel. ⁷⁴Department of Psychiatry and Behavioral Sciences, SUNY Upstate Medical University, Syracuse, NY, USA. ⁷⁵Institute for Genomic Medicine, Columbia University Medical Center, Hammer Health Sciences, New York, NY, USA. ⁷⁶Department of Genetics and Development, Columbia University Medical Center, Hammer Health Sciences, New York, NY, USA. ⁷⁷Centro de Investigacion en Salud Poblacional, Instituto Nacional de Salud Pública, Cuernavaca, Mexico. ⁷⁸Genomics, Diabetes and Endocrinology, Lund University, Lund, Sweden. ⁷⁹Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland. ⁸⁰Lund University Diabetes Centre, Malmö, Sweden. ⁸¹Human Genetics Center, University of Texas Health Science Center at Houston, Houston, TX, USA. ⁸²Department of Neurology, Columbia University, New York, NY, USA. ⁸³Institute of Genomic Medicine, Columbia University, New York, NY, USA. ⁸⁴Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland. ⁸⁵Department of Psychiatry, Helsinki University Central Hospital, Lapinlahdentie, Helsinki, Finland. ⁸⁶Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. ⁸⁷Icahn School of Medicine at Mount Sinai, New York, NY, USA. ⁸⁸Department of Neurology, Helsinki University Central Hospital, Helsinki, Finland. ⁸⁹Department of Public Health, Faculty of Medicine, University of Helsinki, Helsinki, Finland. ⁹⁰Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ⁹¹Center for Genome Science, Korea National Institute of Health, Chungcheongbuk-do, South Korea. ⁹²MRC Centre for Neuropsychiatric Genetics & Genomics, Cardiff University School of Medicine, Cardiff, USA. ⁹³Department of Health, National Institute for Health and Welfare (THL), Helsinki, Finland. ⁹⁴Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, Connecticut Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT, USA. ⁹⁵Division of Pediatric Gastroenterology, Emory University School of Medicine, Atlanta, GA, USA. ⁹⁶Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea. ⁹⁷Institute of Clinical Medicine, The University of Eastern Finland, Kuopio, Finland. ⁹⁸Institute of Clinical Medicine Neurology, Kuopio University Hospital, Kuopio, Finland. ⁹⁹Department of Clinical Chemistry, Fimlab Laboratories and Finnish Cardiovascular Research Center-Tampere, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland. ¹⁰⁰The Mindich Child Health and Development Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹⁰¹Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China. ¹⁰²Hong Kong Institute of Diabetes and Obesity, The Chinese University of Hong Kong, Hong Kong, China. ¹⁰³Cardiovascular Research REGICOR Group, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Catalonia, Spain. ¹⁰⁴Department of Genetics, Harvard Medical School, Boston, MA, USA. ¹⁰⁵Oxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Churchill Hospital, Headington, Oxford, UK. ¹⁰⁶Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. ¹⁰⁷Oxford NIHR Biomedical Research Centre, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK. ¹⁰⁸F Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. ¹⁰⁹Atherogenomics Laboratory, University of Ottawa Heart Institute, Ottawa, Canada. ¹¹⁰Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA. ¹¹¹Department of Clinical Sciences, University Hospital Malmö Clinical Research Center, Lund University, Malmö, Sweden. ¹¹²Department of Clinical Sciences, Lund University, Skane University Hospital, Malmö, Sweden. ¹¹³Instituto Nacional de Medicina Genómica (INMEGEN), Mexico City, Mexico. ¹¹⁴Medical Research Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK. ¹¹⁵Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul, South Korea. ¹¹⁶Department of Psychiatry, Keck School of Medicine at the University of Southern California, Los Angeles, CA, USA. ¹¹⁷Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ¹¹⁸Division of Genetics and Epidemiology, Institute of Cancer Research, London, USA. ¹¹⁹Research Unit of Clinical Neuroscience, University of Oulu, Oulu, Finland. ¹²⁰Research Center, Montreal Heart Institute, Montreal, Quebec, Canada. ¹²¹Department of Medicine, Faculty of Medicine, Université de Montréal, Montreal, Quebec, Canada. ¹²²Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA. ¹²³Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA. ¹²⁴Department of Biostatistics and Epidemiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ¹²⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA. ¹²⁶Center for Non-Communicable Diseases, Karachi, Pakistan. ¹²⁷National Institute for Health and Welfare, Helsinki, Finland. ¹²⁸Deutsches Herzzentrum München, Munich, Germany. ¹²⁹Technische Universität München, Munich, Germany. ¹³⁰Division of Cardiovascular Medicine, Nashville VA Medical Center and Vanderbilt University, School of Medicine, Nashville, TN, USA. ¹³¹Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹³²Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹³³Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. ¹³⁴Institute of Clinical Medicine Neurology, University of Eastern Finland, Kuopio, Finland. ¹³⁵Department of Twin Research and Genetic Epidemiology, King's College London, London, UK. ¹³⁶Departments of Genetics and Psychiatry, University of North Carolina, Chapel Hill, NC, USA. ¹³⁷Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore, Singapore. ¹³⁸Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. ¹³⁹Duke-NUS Graduate Medical School, Singapore, Singapore. ¹⁴⁰Lifesciences Institute, National University of Singapore, Singapore, Singapore. ¹⁴¹Department of Statistics and Applied Probability, National University of Singapore, Singapore. ¹⁴²Folkhälsan Institute of Genetics, Folkhälsan Research Center, Helsinki, Finland. ¹⁴³HUCH Abdominal Center, Helsinki University Hospital, Helsinki, Finland. ¹⁴⁴Department of Psychiatry, Center for Behavioral Genomics, University of California, San Diego, CA, USA. ¹⁴⁵Institute of Genomic Medicine, University of California, San Diego, CA, USA. ¹⁴⁶Juliet Keidan Institute of Pediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel. ¹⁴⁷Instituto de Investigaciones Biomédicas UNAM, Mexico City, Mexico. ¹⁴⁸Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico. ¹⁴⁹Radcliffe Department of Medicine, University of Oxford, Oxford, UK. ¹⁵⁰Department of Gastroenterology and Hepatology, University of Groningen and University Medical Center Groningen, Groningen, The Netherlands. ¹⁵¹Department of Physiology and Biophysics, University of Mississippi Medical Center, Jackson, MS, USA. ¹⁵²Program in Infectious Disease and Microbiome, Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹⁵³Center for Computational and Integrative Biology, Massachusetts General Hospital, Boston, MA, USA. ¹⁵⁸Deceased: Pamela Sklar.

Article

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this paper.

Data availability

All gnomAD-SV site-frequency data for appropriately consented samples ($n = 10,847$) have been distributed in VCF and BED format via the gnomAD browser (<https://gnomad.broadinstitute.org/downloads/>), as well as from NCBI dbVar under accession nstd166. Furthermore, these SVs have been integrated directly into the gnomAD browser⁸. The architecture of the gnomAD browser is described in the main gnomAD study⁴, as well as instructions for how to access and query the data hosted therein.

Code availability

The gnomAD-SV discovery pipeline is publicly available via a series of methods configured for the FireCloud/Terra platform (<https://portal.firecloud.org/#methods>) under the methods namespace 'Talkowski-SV'. The svtk software package used extensively in the gnomAD-SV discovery pipeline is publicly available via GitHub (<https://github.com/talkowski-lab/svtk>). Most custom scripts used in the production and/or analysis of the gnomAD-SV dataset are publicly available via GitHub (<https://github.com/talkowski-lab/gnomad-sv-pipeline>). All code is made available under the MIT license, unless stated otherwise.

Acknowledgements We thank the many individuals whose sequence data are aggregated in gnomAD for their contributions to research, and the users of gnomAD for their collaborative feedback. We are grateful to the families at the participating Simons Simplex Collection (SSC) sites, as well as the SSC principal investigators. We thank T. Heffernan of the NIH National Center for Biotechnology Information for his help hosting gnomAD-SV on dbVar. We have complied with all relevant ethical regulations. Research and contributing authors were supported by resources from the Broad Institute, the National Institutes of Health (NIH) (R01MH115957 to M.E.T., B.N. and D.G.M.; UM1HG008895 to M.J.D., B.N., S.G., E.S.L., S.K., M.E.T.; R01HD081256, P01GM061354, R01HD091797, R01HD096326, R01MH111776, R01HD099547 to M.E.T.; U01MH105669 to M.J.D., B.N. and M.E.T.; P50HD028138 to B.N. and M.E.T.; P01HD068250 to H.B.) and the Simons Foundation for Autism Research Initiative (SFARI #573206 to M.E.T.). R.L.C. was supported by NHGRI T32HG002295 and NSF GRFP #2017240332. H.B. was supported by NIDCR K99DE026824. A.V.K. was supported by NHGRI

K08HG010155. M.E.T. was supported by Desmond and Ann Heathwood. MESA and the MESA SHARe project are conducted and supported by the National Heart, Lung, and Blood Institute (NHLBI) in collaboration with MESA investigators. Support for MESA is provided by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-00107, and UL1-TR-001420. MESA family is conducted and supported by the NHLBI in collaboration with MESA investigators. Support is provided by grants and contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251, R01HL071258 and R01HL071259, by the National Center for Research Resources, grant UL1RR033176, and the National Center for Advancing Translational Sciences ULTR001881, and the National Institute of Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC) grant DK063491 to the Southern California Diabetes Endocrinology Research Center.

Author contributions R.L.C., H.B., K.J.K., X.Z., J.A., L.C.F., C.L., A.O'D.-L., E.V., H.J.L., J.I.R., M.J.D., D.G.M. and M.E.T. contributed to the writing of the manuscript and generation of figures. R.L.C., H.B., K.J.K., X.Z., L.C.F., C.L., L.D.G., H.W., E.V., J.F., M.J.D., E.B., D.G.M. and M.E.T. contributed to the analysis of data. R.L.C., H.B., X.Z., L.D.G., H.W., N.A.W., M.S., A.B., R.M., M.W., C.W., Y.H., T.B., T.S., M.R.S., E.V., J.F., V.R.-R., C.N., A.P., B.M.N., E.B., D.G.M. and M.E.T. developed tools and methods that enabled the scientific discoveries herein. R.L.C., H.B., K.J.K., X.Z., J.A., L.C.F., A.V.K., L.D.G., H.W., N.A.W., M.S., A.O'D.-L., A.B., R.M., G.T., K.M.L., C.S., N.G., C.C., L.M., K.D.T., H.J.L., S.S.R., W.P., Y.-D.I.C., J.I.R., C.N., A.P., E.L., S.G., B.M.N., S.K., M.J.D., E.B., D.G.M. and M.E.T. contributed to the production and quality control of the gnomAD dataset. All authors listed under The Genome Aggregation Database Consortium contributed to the generation of the primary data incorporated into the gnomAD resource. All authors reviewed the manuscript. R.L.C. and H.B. contributed equally to this study.

Competing interests K.J.K. owns stock in Personalis. A.O'D.-L. has received honoraria from ARUP and Chan Zuckerberg Initiative. B.M.N. is a member of the scientific advisory board at Deep Genomics and consultant for Camp4 Therapeutics, Takeda Pharmaceutical, and Biogen. M.J.D. is a founder of Maze Therapeutics. D.G.M. is a founder with equity in Goldfinch Bio, and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Merck, Pfizer, and Sanofi-Genzyme. M.E.T. has received research support from Levo Therapeutics. All other authors declare no competing interests. S.K. is an employee of Verve Therapeutics, and holds equity in Verve Therapeutics, Maze Therapeutics, Catabasis, and San Therapeutics. He is a member of the scientific advisory boards for Regeneron Genetics Center and Corvidia Therapeutics; he has served as a consultant for Acceleron, Eli Lilly, Novartis, Merck, Novo Nordisk, Novo Ventures, Ionis, Alnylam, Aegerion, Haug Partners, Noble Insights, Leerink Partners, Bayer Healthcare, Illumina, Color Genomics, MedGenome, Quest, and Medscape; he reports patents related to a method of identifying and treating a person having a predisposition to or afflicted with cardiometabolic disease (20180010185) and a genetics risk predictor (20190017119).


Additional information

Supplementary information is available for this paper at <https://doi.org/10.1038/s41586-020-2287-8>.

Correspondence and requests for materials should be addressed to M.E.T.

Peer review information *Nature* thanks Don Conrad, Jan Korbel, Tobias Rausch and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Peer reviewer reports are available.


Reprints and permissions information is available at <http://www.nature.com/reprints>.



Extended Data Fig. 1| Detection of chromosome-scale dosage alterations.
We estimated ploidy (that is, whole-chromosome copy number) for all 24 chromosomes per sample. **a**, Distribution of autosome ploidy estimates across 14,378 samples passing initial data quality thresholds. White diamonds indicate medians. Individual points are outlier samples at least three standard deviations away from the cohort-wide mean. The outlier points marked in red and blue correspond to the samples highlighted in **b–e**. **b–e**, Samples with outlier autosome ploidy estimates typically contained somatic or mosaic chromosomal abnormalities, such as somatic aneuploidy of chromosome 1 (chr1) (**b**) or chromosome 8 (**e**), or large focal somatic or mosaic CNVs on chromosome 3 (**c**) and chromosome 7 (**d**). Each panel depicts copy-number

estimates in 1-Mb bins for each rearranged sample in red or blue. Dark, medium and light-grey background shading indicates the range of copy number estimates for 90%, 99% and 99.9% of all gnomAD-SV samples, respectively, and the medium grey line indicates the median copy number estimate across all samples. Regions of unalignable N-masked bases >1 Mb in the reference genome are masked with grey rectangles. **f**, Sex chromosome ploidy estimates for all samples from **a**. We inferred karyotypic sex by clustering samples to their nearest integer ploidy for sex chromosomes. Several abnormal sex chromosome ploidies are marked, including XYY (*i*), XXY (*ii*), XXX (*iii*), and mosaic loss-of-Y (*iv*). **g**, Histogram representation of the data from **f**. Essentially all samples conformed to canonical sex chromosome ploidies.


Article




Extended Data Fig. 2 | Benchmarking the technical qualities of the gnomAD-SV callset.

We evaluated the quality of gnomAD-SV with seven orthogonal analyses detailed in Supplementary Table 4, Supplementary Figs. 6–9 and Supplementary Note 1. Four core analyses are presented here.

a, Apparent rates of de novo (that is, spontaneous) heterozygous SVs per child across 970 parent–child trios. Each point is a single trio, and vertical lines denote medians. Given the expected mutation rate of SVs accessible to short-read WGS^{1,20} (<1 true de novo SV per trio; see also Fig. 3a), effectively all de novo SVs represented a combination of false-positive genotypes in children and/or false-negative genotypes in parents. SVs passing all filters and included in the final gnomAD-SV callset ('pass') are shown in green. For comparison, variants that did not pass post hoc site-level filters ('not pass') are also shown in purple. **b**, Hardy–Weinberg equilibrium (HWE) metrics for all biallelic SVs localized to autosomes. Deviation from HWE was assessed using a chi-square goodness-of-fit test with one degree of freedom. Vertex labels reflect genotypes: 0/0 denotes homozygous reference; 0/1 denotes heterozygous; and 1/1 denotes homozygous alternate, with all sites shaded by chi-squared P value. **c**, Linkage disequilibrium between SVs and SNVs or indels for 23,706 common (allele frequency > 1%) SVs represented as cross-population maximum R^2 values after excluding repetitive and low-complexity regions (see Supplementary Fig. 7). Points and vertical bars represent medians and interquartile ranges, respectively. **d**, Correlation of allele frequency (AF) for 37,907 common SVs captured by both the 1000 Genomes Project and gnomAD-SV¹. Pearson's correlation coefficient (R^2) is provided.




Extended Data Fig. 3 | In silico confirmation of SVs in gnomAD-SV with long-read WGS. We used Pacific Biosciences (PacBio) long-read WGS data available for four samples in this study to perform in silico confirmation to estimate the positive predictive value and breakpoint accuracy for SVs in gnomAD-SV^{21,45,46} (Supplementary Fig. 10). **a**, Counts of SVs evaluated per sample in this analysis. SVs were restricted to those with breakpoint-level read support (that is, ‘split-read’ evidence, 92.8% of all SVs) and did not have breakpoints localized to annotated simple repeats or segmental duplications. **b**, An iterative local long-read WGS realignment algorithm, VaPoR⁴⁷, was used to perform in silico confirmation of SVs predicted from short-read WGS in gnomAD-SV. As noted by the VaPoR developers⁴⁷, the performance of this approach was sensitive to the sequencing depth of long-read WGS data. Therefore, the weighted mean of the four samples was used as a study-wide long-read WGS confirmation rate, weighting the confirmation rate of each sample based on the square root of its long-read WGS sequencing depth. **c**, Confirmation rates stratified by SV class, size and allele frequency. A mean of 4,829 SVs per sample were assessed. Horizontal green bars denote weighted means.




Extended Data Fig. 4 | SVs contribute a substantial burden of rare, homozygous, and coding mutations per genome. **a–d**, Counts of SVs per genome across a variety of parameters, corresponding to median counts of total SVs (**a**), homozygous SVs (**b**), rare SVs (**c**) and singleton SVs (**d**). Samples are grouped by population and coloured by SV types. The solid bar to the left of each population indicates the population median. **e–g**, Median counts of genes disrupted by SVs per genome when considering all SVs (including MCNVs) (**e**), homozygous SVs (including MCNVs) (**f**), and rare SVs (**g**). Colours correspond

to predicted functional consequence. **h**, Counts of pLoF SVs per genome. For certain categories, such as genes disrupted by rare SVs per genome, a subset of samples (<5%) were enriched above the population average, as expected for individuals carrying large, rare CNVs predicted to cause the disruption of dozens or hundreds of genes (see Extended Data Fig. 1); for the purposes of visualization, the y axis for all panels has been restricted to a maximum of three interquartile ranges above the third quartile across all samples for each category.




Extended Data Fig. 5 | Rearrangement size is a primary determinant of allele frequency for most classes of SVs. **a**, Proportion of singleton SVs in five SV size bins for each class of biallelic SVs considered in this study. Intergenic SVs (light colours; $n = 206,954$) exhibited reduced singleton proportions when compared to all SVs (dark colours; $n = 335,470$) of the same size and class. Bars reflect 95% confidence intervals from 100-fold bootstrapping. Categories with fewer than ten SVs are not shown. **b**, To account for the strong dependency of singleton proportion on SV size and class, we developed the APS metric, which normalizes singleton proportions using SV-specific technical and genomic covariates to permit comparisons of the frequency spectra across SV classes

(see Supplementary Fig. 14). The same data as in **a** are shown, transformed onto the APS scale, which shows effectively no dependency on SV size for intergenic SVs. Bars reflect 95% confidence intervals from 100-fold bootstrapping. Residual deviation from APS = 0 is maintained when considering all SVs, owing to APS being intentionally calibrated to intergenic SVs as a proxy for neutral variation. Because larger SVs are more likely to be gene-disruptive, they upwardly bias the APS point estimates due to residual negative selection not captured by SV size alone. Counts of SVs per category for both **a** and **b** are listed in Supplementary Table 9.



Extended Data Fig. 6 | Most SVs within genes appear under negative selection. **a**, Enrichments for pLoF consequences among rare and singleton SVs across SV classes. **b**, Enrichments for non-pLoF functional consequences among rare and singleton SVs across SV classes. **c**, Adjusted proportion of singletons across SV types and functional consequences. **d**, APS among deletions relative to count of exons and whole genes deleted. **e**, Fractions of all autosomal protein-coding genes with at least one SV across a variety of functional consequences. **f**, Relationship of APS and constraint against pLoF

SNVs⁴. For this analysis, intronic, promoter and UTR SVs were required to have precise breakpoints (that is, have ‘split-read’ support) to protect against any cryptic overlap with coding sequence unable to be annotated due to imprecise breakpoints. For **c**, **d** and **f**, points and vertical bars represent 95% confidence intervals from 100-fold bootstrapping, respectively. Counts of SVs per category in **c** and **d** are provided in Supplementary Table 9. For **d** and **f**, deletions in highly repetitive or low-complexity sequence ($\geq 30\%$ coverage by annotated segmental duplications or simple repeats) were excluded.



Extended Data Fig. 7 | gnomAD-SV can augment disease association studies.

a, Functional enrichments of 2,307 common SVs in strong linkage disequilibrium ($R^2 \geq 0.8$) with an SNV associated with a trait or disease in the GWAS catalogue or the UK Biobank^{33,34}. Points represent odds ratios of SVs being in strong linkage disequilibrium with at least one GWAS-significant SNV among all SVs in strong linkage disequilibrium with at least one SNV (total $n=15,634$ SVs). Single and triple asterisks correspond to nominal ($P < 0.05$) and Bonferroni-corrected ($P < 0.0083$) significance thresholds from a two-sided Fisher's exact test, respectively. Bars represent 95% confidence intervals. Test statistics, SV counts, and P values are provided in Supplementary Table 6.

b, Example locus at 16q22.1, where we identified a 336-bp deletion in strong linkage disequilibrium with SNVs significantly associated with hypothyroidism in the UK Biobank³⁴. Top, the GWAS signal among genotyped SNVs in the UK Biobank, coloured by strength of linkage disequilibrium (Pearson's R^2 value) with the 336-bp deletion identified in gnomAD-SV. Bottom, the local genomic context of this deletion, which overlaps an annotated intronic *Alu* element near (<1 kb) the first exon of a highly constrained, thyroid-expressed gene, *ATP6V0D1*. The deletion lies amidst histone mark peaks commonly found at active enhancers (H3K4ac and H3K4me1) based on publicly available chromatin data from adult thyroid samples, a phenotype-relevant tissue⁴⁸. Human *Alu* elements are known to frequently act as enhancers, and the sentinel hypothyroidism SNV from the UK Biobank GWAS is a significant expression-modifying variant (that is, eQTL) for *ATP6V0D1* and other nearby genes across many tissues, which indicates that the hypothyroidism risk haplotype modifies expression of *ATP6V0D1* and/or other genes, potentially through the deletion of an intronic enhancer⁴⁹.

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see [Authors & Referees](#) and the [Editorial Policy Checklist](#).

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
Only common tests should be described solely by name; describe more complex techniques in the Methods section.
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F , t , r) with confidence intervals, effect sizes, degrees of freedom and P value noted
Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d , Pearson's r), indicating how they were calculated

Our web collection on [statistics for biologists](#) contains articles on many of the points above.

Software and code

Policy information about [availability of computer code](#)

Data collection

All software used for data collection is described in the Methods. All software is publicly available, and all custom software developed in this study has been released under the MIT license. Details on code access are provided in Supplementary Information.

Data analysis

All software used for data analysis is described in the Methods. All software is publicly available, and all custom software developed in this study has been released under the MIT license. Details on code access are provided in Supplementary Information.

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research [guidelines for submitting code & software](#) for further information.

Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The entire gnomAD-SV reference map, from which all conclusions in the study are drawn, has been made publicly accessible through multiple sources. See the Data Availability Statement in the Supplementary Information for more instructions on data access.

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	No statistical analyses were performed to predetermine sample size. Sample size was dictated by the total number of human whole-genome sequences available with appropriate consent for genetic data aggregation and variant site & frequency release.
Data exclusions	A minority of samples were excluded for various analyses. Where applicable, these exclusions are detailed in the main manuscript, Methods, and Supplementary Information
Replication	No replication was attempted.
Randomization	No randomization was necessary as most analyses were performed on all available samples.
Blinding	No blinding was performed, as no comparisons between subsets of samples were conducted.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Materials & experimental systems

- | | |
|-----|-----------------------|
| n/a | Involved in the study |
|-----|-----------------------|
- Antibodies
 Eukaryotic cell lines
 Palaeontology
 Animals and other organisms
 Human research participants
 Clinical data

Methods

- | | |
|-----|-----------------------|
| n/a | Involved in the study |
|-----|-----------------------|
- ChIP-seq
 Flow cytometry
 MRI-based neuroimaging

Human research participants

Policy information about [studies involving human research participants](#)

Population characteristics The samples analyzed in this study were aggregated across numerous population genetic and complex disease association studies. This aggregation is described in detail in the Methods, and in Karczewski et al., 2019.

Recruitment Samples were not recruited directly by this study. Data aggregation is described in detail in the Methods, and in Karczewski et al., 2019.

Ethics oversight This study was overseen by the Broad Institute's Office of Research Subject Protection and the Partners Human Research Committee, and was given a determination of Not Human Subjects Research.

Note that full information on the approval of the study protocol must also be provided in the manuscript.